InflaRx N.V.
http://www.inflarx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From InflaRx N.V.
InflaRx Picks Outcomes-Based Reimbursement For COVID-19 Drug
The model, more common with high-cost gene therapies, is designed to de-risk use of the drug for hospitals in the event that patients with COVID-19-related ARDS do not survive.
Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering
Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.
Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings
EU marketing authorization applications have been submitted for a number of new drugs, including Eli Lilly’s donanemab, Italfarmaco's givinostat and Arcturus Therapeutics/CSL’s ARCT-154.
InflaRx Looks Ahead To Late 2023 Commercial Sales For COVID-19 Antibody
The price will be more expensive than prior COVID-19 antibodies, reflecting its target to critically ill patients who are hospitalized.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- InflaRx GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice